Guardant Health, Inc. - Common Stock (NQ:GH)

185.18 +7.38 (+4.15%)

Delayed Quote Updated: 2:13 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Guardant Health, Inc. - Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

23 24 Next >

Guardant Health to Ring the Nasdaq Opening Bell on August 28 to Celebrate the Launch of Shield™ Blood Test for Colorectal Cancer Screening

August 22, 2024

From Guardant Health, Inc.

Via Business Wire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

August 12, 2024

The widely followed growth investor was a buyer at the end of a very volatile trading week.

Via The Motley Fool

Cathie Wood's Ark Invest Continues Loads Up On $6.05M Worth Of Robinhood Shares Amid Bitcoin Rebound, Dumps Zoom Stock ↗

August 08, 2024

On Thursday, Cathie Wood-led Ark Invest made some significant trades, notably buying Robinhood Markets Inc (NASDAQ:HOOD) and selling Zoom Video Communications Inc (NASDAQ:ZM).

Via Benzinga

Guardant Health to Participate in Upcoming Investor Conferences

August 08, 2024

From Guardant Health, Inc.

Via Business Wire

Key Takeaways From Guardant Health Analyst Ratings ↗

August 08, 2024

Via Benzinga

Assessing Guardant Health: Insights From 7 Financial Analysts ↗

July 17, 2024

Via Benzinga

Where Guardant Health Stands With Analysts ↗

June 28, 2024

Via Benzinga

GH Stock Earnings: Guardant Health Beats EPS, Beats Revenue for Q2 2024 ↗

August 07, 2024

GH stock results show that Guardant Health beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.

Via InvestorPlace

Guardant Health Reports Second Quarter 2024 Financial Results and Increases 2024 Revenue Guidance

August 07, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer

August 07, 2024

From Guardant Health, Inc.

Via Business Wire

Why Exact Sciences, Up 20%, Is 'Coiled To Snap Back' After Quarterly Beat ↗

August 01, 2024

The company expects stronger second-half sales vs. the first half of 2024.

Via Investor's Business Daily

Guardant Health’s FDA-approved Shield™ Blood Test Now Commercially Available in U.S. as a Primary Screening Option for Colorectal Cancer

August 01, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health Outcomes Model Confirms the Public Health Importance of Enhanced Colorectal Cancer Screening Outcomes with High Adherence Strategies

August 01, 2024

From Guardant Health, Inc.

Via Business Wire

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought ↗

July 31, 2024

The strugglingh stock investor did a little bit of shopping on Tuesday, adding to some of her existing positions.

Via The Motley Fool

FDA Greenlights Guardant Health's Shield Blood Test, Analyst Cautious on Adoption ↗

July 29, 2024

FDA approves Guardant Health's Shield blood test for colorectal cancer screening in adults 45+, marking the first FDA-approved blood test as a primary CRC screening option. Shield meets Medicare...

Via Benzinga

Guardant Health’s Shield™ Blood Test Approved by FDA as a Primary Screening Option, Clearing Path for Medicare Reimbursement and a New Era of Colorectal Cancer Screening

July 29, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Report Second Quarter 2024 Financial Results on August 7, 2024

July 24, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health Introduces Major Smart Liquid Biopsy Upgrade to Market-Leading Guardant360® Test, Further Extending Its Best-in-Class Performance

July 23, 2024

From Guardant Health, Inc.

Via Business Wire

Goldman Sachs Says Buy These 3 Stocks for Double-Digit Returns ↗

July 22, 2024

The investment banking firm says these companies are among the best stocks to buy and have some strong tailwinds behind them.

Via InvestorPlace

3 Precision Medicine Stocks Tailoring Treatments ↗

July 21, 2024

With technological developments pushing the boundaries of healthcare, these are the precision medicine stocks to consider.

Via InvestorPlace

Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast ↗

July 18, 2024

Via Benzinga

Dr. Manuel Hidalgo Medina Joins Guardant Health Board of Directors

July 18, 2024

From Guardant Health, Inc.

Via Business Wire

3 Biotech Moonshots With Imminent Catalyst Potential ↗

July 03, 2024

Biotech has been one of the most explosive sectors. Better, further upside is likely, thanks to some of the top biotech stocks with catalysts.

Via InvestorPlace

The 3 Best Personalized Medicine Stocks to Buy in July 2024 ↗

July 03, 2024

Explore promising personalized medicine stocks poised for growth as the industry expands, driven by advancements in genomic technologies.

Via InvestorPlace

From ‘Sell’ to ‘Strong Buy’: 3 Dramatic Analyst U-Turns to Watch ↗

July 02, 2024

These are three stocks with analyst upgrades worth looking into thanks to their niche specializations and long-term prospects.

Via InvestorPlace

Guardant Health introduces new Guardant360 TissueNext test with nearly 500 biomarkers to identify more treatment options for patients with advanced cancer

June 04, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health and Washington University to present study at 2024 ASCO meeting highlighting utility of ctDNA to address racial inequities in the use of targeted therapies and enrollment in clinical trials

June 03, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health Named to TIME100 Most Influential Companies

May 31, 2024

From Guardant Health, Inc.

Via Business Wire

Guardant Health to Present Studies at 2024 ASCO Annual Meeting Highlighting Contributions of Its Blood Tests and Real-World Data to Advancing Precision Oncology and Cancer Screening

May 30, 2024

From Guardant Health, Inc.

Via Business Wire

Cathie Wood-LedArk Invest Cuts Robinhood Holdings Amid Bitcoin Dip, Keeps Selling Moderna Stock — Buys Palantir And AMD Shares ↗

May 29, 2024

On Wednesday, Ark Invest, led by the influential investor Cathie Wood, executed notable trades involving Robinhood Markets Inc (NASDAQ:HOOD), Moderna Inc (NASDAQ:MRNA), Palantir

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.